Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
DB-1303 by BioNTech for Gastric Cancer: Likelihood of Approval
DB-1303 is under clinical development by BioNTech and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...
DB-1303 by Duality Biologics (Shanghai) for Metastatic Breast Cancer: Likelihood of Approval
DB-1303 is under clinical development by Duality Biologics (Shanghai) and currently in Phase III for Metastatic Breast Cancer. According to...
DB-1303 by Duality Biologics (Shanghai) for Adenocarcinoma: Likelihood of Approval
DB-1303 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Adenocarcinoma. According to GlobalData, Phase...
DB-1303 by Duality Biologics (Shanghai) for Vaginal Cancer: Likelihood of Approval
DB-1303 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Vaginal Cancer. According to GlobalData,...
DB-1303 by BioNTech for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
DB-1303 is under clinical development by BioNTech and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive...
DB-1303 by BioNTech for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
DB-1303 is under clinical development by BioNTech and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to...
DB-1303 by BioNTech for Endometrial Cancer: Likelihood of Approval
DB-1303 is under clinical development by BioNTech and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...
DB-1303 by BioNTech for Solid Tumor: Likelihood of Approval
DB-1303 is under clinical development by BioNTech and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...